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Laron Syndrome, eponymously named after the scientist Zvi 
Laron who first discovered the syndrome, is a growth hormone 
insensitivity syndrome. People with Laron Syndrome have a ge-
netic mutation in the growth hormone receptor. These patients 
have a normal level of growth hormone but a reduced level of 
Insulin-like Growth Factor 1 (IGF-1) and are characterized by 
dwarfism and other physical deformities. Remarkably, patients 
with this condition have been proven to be immune to cancer. 
Through research on Laron Syndrome scientist have found a 
link between a key growth hormone and resistance to cancer.
Methods and Materials
Information was compiled from various articles that were ob-
tained through Touro College’s library database and Pubmed. 
The information was narrowed down to those directly related 
to the topic. The information extracted and synthesized was 
used to hypothesize why Laron Syndrome patients are immune 
to cancer.
Background information
Data shows that Laron Syndrome (LS) patients have normal lev-
els of, and a normal, GH molecule, but a defect in the Growth 
Hormone Receptor gene (GHR). Patients with LS have either a 
gene deletion or a point mutation in this gene (Wood & Savage, 
1996).
Mutations in the growth hormone receptor interrupts the JAK- 
STAT signaling pathway which stimulates the production of 
IGF-1. The JAK-STAT signaling pathway brings information from 
chemical signals outside the cell, through the cell membrane, 
and into the cell where gene promoters on the DNA in the cell 
nucleus can causes DNA transcription and activity in the cell. 
The mutation in the Growth Hormone Receptor, leads to an 
inability of the extracellular domain to bind growth hormone 
and stimulate the production of IGF-1 (Gastier et al., 2000).
Cited from Rosenbloom and Guevara-Aguirre that in 1966, 
Laron, Pertzelan and Mannheimer did research on the high 
levels of growth hormones in patients with clinical and labo-
ratory signs of growth hormone deficiency (Rosenbloom and 
Guevare-Aguirre, 1998). There are ~251 reported people with 
this syndrome. One hundred and forty eight are known to have 
Semitic origin. One third of the people with this syndrome live 
in Loja, Ecuador which is where most of the genetic studies take 
place. The people in Loja, Ecuador are said to have ancestors 
who converted to Christianity during the Spanish Inquisition 
(Wood & Savage, 1996).
Laron syndrome is a congenital autosomal recessive disorder. The 
parents of an individual with Laron syndrome must each have a 
copy of the mutated gene while displaying no signs of the syn-
drome. People with Laron Syndrome have postnatal growth fail-
ure; it begins with “subnormal birth length, retarded brain growth, 
acromicria, also of the facial bone, defective and crowded teeth, 
sparse hair, small gonads and genitalia, obesity, retarded skeletal 
maturation, delayed puberty, hypoglycemia. As these patients get 
older they have obesity, muscle underdevelopment and weak-
ness, osteoporosis, hypercholesterolemia, hyperinsulinemia, and 
various degrees of glucose intolerance (Yamamoto et al, 2007).” 
There is wide phenotypic variability among patients with this 
syndrome. With that said, there is uncanny similarity between 
patients with LS even with variability in genotype and even if they 
are from different places. In the image below of two men with 
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Laron Syndrome, it is evident that there is a similarity in physical 
features. 
The man in figure A and C is 21 years old with a height of 126.6 
cm. The man in B and D is 28 years old and has a height of 115 
cm. Analysis of the faces indicate different craniofacial pheno-
type, but still both men with Laron Syndrome have an uncanny 
resemblance (Rosenbloom and Guevare-Aguirre, 1998).
Patients with LS have extremely low levels of insulin-like growth 
factors, below the 0.1st percentile for age, such as IGF-I which 
is the major hormone responsible for growth and it is under the 
control of GH. Patients with GHD also have a low level of IGF-I 
but those patients responded well to exogenously administered 
GH, whereas patients with LS did not which is a characteristic 
of LS. This is the primary difference between GHD and GHRD. 
LS patients also have extremely low levels of Insulin-like growth 
factor binding proteins (IGFBPs). Specifically, IGFBP-3 levels are 
decreased in LS patients (Wood & Savage, 1996).
Insulin-like growth factor 1 (IGF-1)
IGF-1 is a 70 amino acid polypeptide hormone involved in en-
docrine, paracrine, and autocrine functions. An original name for 
this hormone was somatomedin C because it was under the 
control and mediates the effect of the growth hormone. The 
name was changed to Insulin-like because it shared a similarity 
to proinsulin. Also, it mimics insulin activity such as stimulating 
glucose uptake in the cells. Additionally, IGF-1 has mitogenic ca-
pabilities (Puche & Castille-Cortazar, 2012).
Synthesis and Circulation
Growth hormone is secreted by the pituitary gland and it stim-
ulates the production of IGF-1 by acting on the liver where 
it is made. The pituitary gland releases GH and it works 
together with the liver in a negative feedback mechanism to 
stimulate the secretion of IGF-1; increased levels of IGF-1 
cause a decrease in production of GH which stimulates the 
production of less IGF-1 (Puche & Castille-Cortazar, 2012).
Recent research by Puche and Castille-Cortazar is uncov-
ering IGF-1 as an independent and self-sufficient peptide, 
separate from GH. IGF-1 is produced mainly by the liver 
in response to the endocrine GH stimulus, but it is also 
secreted by multiple tissues for autocrine and paracrine 
purposes.  In tissues throughout the body it is evident that 
IGF-1 expression is regulated and stimulated by other fac-
tors besides GH, such as estrogen in the uterus (Puche & 
Castille-Cortazar, 2012). 
The stimulatory role of IGF-1 on intrauterine growth is 
GH-independent. Regardless of the levels of GH, IGF-1 
deficiency is the main determinant of a reduced birth size. 
(Puche & Castille-Cortazar, 2012). 
Research done on the effects of GH to stimulate skeletal 
growth has proven that GH directly stimulates bone growth. 
Additionally, GH stimulates the production of IGF-1 which 
will then promote bone growth. This proves, along with 
other findings, that IGF-1 and GH work independently and 
synergistically to promote postnatal body growth (Puche & 
Castille-Cortazar, 2012).
Central nervous system development
IGF-1 binds to IGF-1R a cell surface receptor. When IGF-1 
binds to the receptor intracellular signaling is initiated. The 
AKT signaling pathway, which is a stimulator of cell growth 
and proliferation, and a potent inhibitor of programmed cell 
death, is activated.
IGF-1 production coincides with periods of neuron progenitor 
proliferation and differentiation. The role of IGF-1 in the brain 
is not only neuronal produced IGF-1. Systemic IGFs (mainly 
produced by the liver) can cross the blood-brain-barrier and 
are also involved in these processes. Labeled IGFs were placed 
in the carotid arteries of rats and were later on detected in 
the choroid plexus, median eminence, brain arterioles, and 
parenchyma. This coincides with the data that confirmed the 
presence of IGF-1 receptors in the brain capillary endothelial 
cells which constitutes the BBB, and the role in internalizing 
IGFs from circulation to the CNS. There is evidence that 
growth factors, GH, basic fibroblast growth factor; nutrition; 
and injury influence and regulate IGF-1 expression in the brain. 
All of the growth abnormalities that are attributed to LS pa-
tients (see above), indicate that IGF-1 plays a critical role on 
brain development and function. 
Current therapeutic options and limitations
In 1980, Recombinant Human IGF-1 (rhIGF-1), Mecasermin 
became available for experimental therapy for people with se-
vere primary IGF-1 deficiency. An average of 8.5 cm in height 
was grown the first year. Besides for an increase in height, pa-
tients with rhIGF-1 treatment had an increase in testosterone 
levels, testicular size and stretched penile length. This shows 
the effect of IGF-1 on sex hormones and organs in male pa-
tients (Puche & Castile-Cortazar, 2012).  
Another treatment that the FDA approved was a combination 
of IGF-1 and IGFBP-3, Mecasermin Rinfabate. This was thought 
to have been a smarter alternative to Recombinant human 
insulin growth factor 1 (rhigf-1) because it was supposed to 
extend the duration of IGF-1 in the body. Interestingly enough, 
when the combination of IGF-1 and IGFBP-3 were used to 
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treat patients compared to a control group who only were 
treated with IGF-1, those treated with IGF-1 alone had better 
results (Puche & Castile-Cortazar, 2012). 
Dosing guidelines for rhIGF-1 are still being debated. The in-
ternational Congress of Endocrinology has stated that both 
one and two injections of rhIGF-1 is safe and efficient. One 
or two injections regimen have the same growth velocity. By 
carefully monitoring the IGF-1 serum levels the negative side ef-
fects can be avoided. Long-term rhIGF-1 has reported negative 
side effects. These side-effects, namely tachycardia were easily 
managed without treatment discontinuation (Puche & Castile-
Cortazar, 2012). 
A novel and efficient method for hormone replacement therapy 
is being developed using Sertoli cells. Sertoli cells are original-
ly from the male testis, and they can ameliorate development 
and survival and function of different cell types. In the “Laron 
mouse” it was successfully reported that pre-pubertal sertoli 
cells in microcapsules can successfully promote growth. There 
was a significant increase in body weight and body length com-
pared with the control “Laron mouse” treated with empty cap-
sules.  IGF-1 serum levels were noticeably increased in mice 
treated with Sertoli cells microcapsules.  The reduction in side 
effects, the increase in growth, and the fact that sertoli cells 
do not require intramuscular daily injections are all reasons 
that sertoli cell treatment is preferred over rhigf-1 treatment 
(Kinam Park, 2012).
Puche and Castille-Cortazar cite a study done by Steuerman R, 
Shevah O, Laron Z. on the prevalence of cancer in people with 
Laron Syndrome compared to their family members. This study 
proved that IGF-1 deficiency provides protection against cancer. 
Interestingly, this study reported that Laron Syndrome patients 
are protected against future cancer development, even when 
treated with rhIGF-1. (Puche & Castile-Cortazar,  2012).
The positive results of exogenously administered IGF-1 in sub-
jects without  IGF-1 deficiency, to use its anti-inflammatory, 
hematopoietic, antioxidant, metabolic or anabolic properties,  is 
not clearly determined (Puche & Castile-Cortazar,  2012).
Discussion
Studies have shown that patients with overexpression of IGF-I 
are more susceptible to tumors. Laron set out to determine 
if patients with IGF-I deficiency (LS) are less likely to develop 
cancer. Two hundred and twenty eight patients with IGF-1 defi-
ciency and 338 of first and second degree family members were 
surveyed. Cancer was not a cause of death in GHRD patients of 
any age. Ten to twenty four percent of the family members had a 
history of malignancies. Only one GHRD subject monitored had 
cancer, papillary serous epithelial tumor in the ovary. The table 
below shows the prevalence of the malignancies in patients and 
family members.  Because of the results of this and further stud-
ies, IGF-I receptor blockers are being developed as drugs for 
cancer therapy (Shevah & Laron, 2006)
What is the link between GH and cancer? 
Data suggest that the GH/IGF-1 axis shows an important role 
in cancer.
Growth Hormone does not have the ability to induce cancer, 
but it has cancer-enhancing properties. There are many differ-
ent factors that influence the different effects of the IGF-1. The 
powerful effects of IGF-1 on the stages of cancer development 
and behavior include “cellular proliferation and apoptosis, an-
giogenesis and metastasis…” Additionally, IGF-1 is a powerful 
antiapoptotic agent. These opposing effects relate strongly to 
cancer. Firstly, there is increased proliferation causing epithe-
lial cell turnover within tissues. Secondly, there is an imbalance 
in the control between proliferation and cell death because of 
the anti-apoptotic effects which leads to hyperproliferation. 
This is the first stage of development of many cancers. Thirdly, 
this imbalance between cell proliferation and cell death causes 
the favoring of cell survival even in damaged cells. This could 
Prevalence of malignancy in the surveyed subjects
Diagnosis Patients Malignacy Relatives Malignacy
Israeli Cohort
Laron syndrom n=40a 0 n=99 n=24(24.2%)
M:F 18:22 2:49:00 15:08
Age Range 3–75 19–91 42–81
Mean age 32.3 55.4 51
Other diagnosis n=22 0 n=83 n=7(10%)
M:F 13:09 19:40:00 3:04
Age Range 3–56 5–93 32–80
Mean Age 27 51.4 64.8
Other Countries
Laron syndrom n=129 0 n=151 n=17(11.2%)
M:F 59:70 78:73 8:09
Age Range 6–78 27–68 45–85
Mean Age 16 50 68
Other diagnosis n=31 0 n=5 n=3
M:F 19:12 3:02 2:01
Age Range 2.5–50 40–80 68–80
Mean Age 16.8 60 65
(Laron & Shevah, 2006)
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accelerate carcinogenesis. Both the second and third point are 
ways that cancer is accelerated not initiated (Puche & Castile-
Cortazar, 2012).
Research in epidemiological studies have shown a correlation 
between the role of GH and carcinogenesis. People with more 
growth hormone are naturally taller.  The Boyd-Orr study 
showed an SD of 1 inch height to be linked with a 42% higher 
risk of cancer later in life in boys. High birth weight, high stature 
at 14, low body mass index, and peak growth at early age were 
independent risk factors for breast cancer. (Jenkins et. al., 2005) 
Epidemiological date found a correlation between adult height 
and cancer. An increase in breast cancer by 22 % was noted with 
increased height. These studies suggest that the GH/IGF-1 axis 
plays an important role in cancer development and behavior 
(Jenkins et. al., 2005). Many pharmaceutical companies are creat-
ing drugs that inhibit the IGF-1 signaling to inhibit breast cancer 
proliferation and block the mitogenic effects of exogenous IGF-
1. They are also experimenting with Inhibitors of the IGF-IR as a 
chemotherapeutic (Jenkins et. al., 2005).
Studies on mice were done to provide evidence to this rela-
tionship. Transgenic mice with human GH and agonist for the 
IGF-1 receptor have increased incidence of breast tumor de-
velopment. On the other hand, mice with a non-functioning GH 
receptor (serum GH/IGH-1 levels of ten percent the normal), 
showed inhibition of growth of transplanted breast cancer cells. 
Even the serum was less mitogenic to breast cancer cells in 
vitro than a control serum, this changed once IGF-1 was added 
to the serum. Recent studies have shown that mice transfected 
with growth hormone receptor antagonists have less incidences 
of carcinogenesis (Guevara-Aguirre et. al., 2011). 
Another study done on mice was used to prove the influen-
tial effects IGF-1 exerts on the metastatic power of cancers 
(Guevara-Aguirre et. al., 2011). This is an extremely important 
aspect of cancer as the metastatic spread of cancer is usually 
what causes mortality. A cell from the LCC6 metastatic breast 
cancer cell line was transfected with a truncated IGF-1 receptor 
that silenced the expression of IGF-1 receptor and inhibited 
IGF-1 signaling. These cells were transplanted into mice and the 
metastatic spread was measured. Mice that were transplanted 
with wild type cells had multiple pulmonary metastases, but the 
mice transplanted with the transfected cells were completely 
absent of any metastases (Guevara-Aguirre et. al., 2011).  
Another reason how the GH/IGF-1 axis can cause cancer is 
by promoting an increased DNA damage. Experiments on 
Saccharomyces cerevisiae yeast indicate that mammalian growth 
signaling pathway genes promote an increase in DNA muta-
tions by elevating superoxide production and increasing DNA 
damage. This is particularly important because it hypothesizes 
that, in addition to the possibility that the GH/IGF-1 axis may 
promote cancer by preventing apoptosis of the damaged cells, 
it can increase DNA damage in cells that can ultimately lead 
to cancer. To test this hypothesis, human mammary epithelial 
cells (HMECs) were placed in a medium that contained 15% 
serum from either Laron syndrome subjects or their relatives. 
The cells were then treated with H2O2 followed by comet anal-
ysis to detect DNA strand breaks. The comet analysis indicated 
that cells incubated in serum from GHRD patients had fewer 
DNA breaks after treatment in comparison to cells incubated in 
serum from relatives. This teaches that serum from GHRD sub-
jects can protect against oxidative DNA damage independently 
of cell division. It was determined that that IGF-1 signaling was 
responsible for the sensitization of cells to oxidative damage via 
analysis of DNA damage in MEF cells lacking the IGF-R or over-
expressing the human IGF-1R cell (R+ cells). R+ cells had more 
DNA damage than did R-cells. (Guevara-Aguirre et. al., 2011).
A study done by Wang and colleagues on rats explains that 
down-regulation of GH signaling could block carcinogenesis in 
rats. Human prostate cancer cell lines express GH receptors 
at levels greater than normal.  A rat that does not have GH 
because of a mutation was crossed with the Probasin/Tag rat, 
a rat which develops prostate carcinomas at 100% incidence 
rate. The rats that were homozygous for the GH deficiency had 
prostrate tumor incidence and tumor latency reduced relative 
to wild type rats. At 25 weeks of age, the rats with no GHR 
resulted in a 20% and 80% decrease of carcinoma in the dorsal 
and lateral lobes, respectively. At 52 weeks of age, invasive pros-
tate adenocarcinomas were observed in all Probasin/ Tag rats 
positive for the Growth Hormone. Conversely, majority of the 
Tag rats with the mutation that makes them GH deficient did 
not develop invasive tumors (Wang et. al. 2008).
The potent antiapoptotic and mitogenic properties of IGF-1 
is linked to an increased risk in developing cancer. It is docu-
mented that IGF-1 can promote carcinogenesis at the cellular 
(Svensson et. al., 2012)
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level, but evidence is accumulating that circulating IGF-1 can 
also promote carcinogenesis. For example, reduction of IGF-1 
by dietary restriction slows tumor progression and increase 
apoptosis in tumor cells of animal models. And when these 
models were treated with recombinant IGF-1 the effects were 
reversed. Additionally, IGF-1 gene deletion in mice is linked to 
a 75% decrease in circulating IGF-1 levels. Tumor growth and 
development was much higher in the control group than trans-
genic mice. 
Biological interactions among insulin, IGF-1 and 
IGFPBS
As stated above there are many clinical studies that suggest that 
high serum IGF-1 levels associate with increased risk of cancer. 
Increasing clinical evidence suggests that low IGF-1 levels are as-
sociated with cancer mortality in older men. In numerous stud-
ies, the association between circulating IGF-1 levels and cancer 
mortality was U-shaped with increased levels of mortality at 
both the low and high serum IGF-1 levels.
Serum IGF-1 was extracted from the blood of a large cohort of 
elderly men from Sweden. The measurements of serum IGF-1 
levels were obtained. The reason for mortality was documented 
on the death certificate of the subjects and then used in the 
study. Cox proportional hazards was used to analyze the associ-
ation between serum IGF-1 levels and mortality by cancer. Cox 
regression analysis showed that both low and high serum IGF-1 
concentration was associated with increased cancer mortality. 
The patients with a history of cancer were excluding from the 
analysis (Svensson et al, 2012).
IGF-1R Inhibitors as an Anti-Cancer
Because of the role that IGF signaling plays in the promotion 
of cell growth and inhibition of apoptosis, IGF blocking is being 
developed as a therapeutic potential to protect against cancer. 
Currently there are many clinical studies targeting and inhib-
iting the IGF pathway to promote anti-tumor activities. There 
are three main classes of IGF/IGF-1R inhibitor antibodies being 
studied in clinical trials; each class inhibits IGF-1R signaling 
but through different mechanisms. There has been some small 
success in treating patients with select tumor types, but many 
trials have been unsuccessful. Researchers are trying to identify 
patient selection markers to attain future success in IGF-1R in-
hibitor development (Chen & Sharon, 2013).
IGF blocking is also being used to overcome chemotherapy 
sensitivity. Resistance to chemotherapy is common nowadays. 
IGF is implicated in chemotherapy resistance because it pro-
motes proliferation and inhibits apoptosis.  Researchers have 
tested this hypothesis and have found that IGF-1R inhibitors 
have caused significant tumor growth inhibition. Currently, 
researchers are testing the combined effect of IGF-1R inhibitors 
with a chemotherapeutic (Weroha & Haluska, 2008).
Conclusion
Laron Syndrome subjects participate in groundbreaking genetic 
studies to explore the relationship between the deficiency in 
the growth hormone receptor and immunity to cancer. This 
syndrome is providing insight to, and revolutionizing, the way 
cancer is treated and prevented. Because Laron Syndrome sub-
jects have decreased levels of IGF-1 they are protected against 
numerous and potentially harmful effects of IGF-1 including cel-
lular proliferation, apoptosis, angiogenesis, and metastasis. The 
increased proliferation and decreased apoptosis causes survival 
of damaged cells that then spread easily throughout the body, 
which could lead to the development of cancer. Because Laron 
Syndrome subjects have decreased levels of IGF-1 they are 
immune to cancer.  The implications of IGF/IGF-1R in cancer 
development, maintenance, and progression, is what led to rep-
licating the IGF-1 levels of LS patients to use as an anti-cancer 
target. IGF-1 has been successfully inhibited in animal models to 
prevent cancer cell growth. Now researchers are beginning to 
use IGF-1 reducing agents and blockers as a chemotherapeutic 
to prevent cancer.
Abbreviations
IGF-1 Insulin Growth Factor 1
LS Laron Syndrome
GH Growth Hormone
GHR Growth Hormone Receptor
GHD Growth Hormone Deficiency
GHRD Growth Hormone Receptor Deficiency
CNS Central Nervous System
rhIGF-1 Recombinant Human Insulin Growth Factor 1
IGFBP Insulin Growth Factor Binding Proteins
HMEC Human Mammary Epithelial Cells
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